2026年非肌层浸润性膀胱癌诊断与治疗更新:AUA/SUO指南
更新涉及生物标志物、亚型组织学、经尿道切除、膀胱内治疗、卡介苗(BCG)维持、增强膀胱镜及未来方向等陈述,旨在改善临床评估与治疗能力。
要点
- 更新NMIBC风险分层及生物标志物、亚型组织学相关陈述。
- 涉及经尿道切除、膀胱内治疗及BCG维持的推荐更新。
- 增强膀胱镜及未来方向亦纳入本次修订范围。
核心结论
- 本次指南更新旨在基于现有证据提升临床医生对NMIBC患者的评估与治疗能力。
- 未来研究对进一步支持或细化这些陈述以改善患者照护至关重要。
研究设计与样本
- 指南更新采用改良版检索策略系统检索Ovid MEDLINE和Embase。
- 系统检索识别2933项研究,经标题摘要筛选后71项符合纳入标准。
- 全文审查后最终证据库纳入38项研究。
主要发现
- 更新涉及NMIBC风险分层及生物标志物相关陈述。
- 更新涉及亚型组织学、经尿道切除和膀胱内治疗相关陈述。
- 更新涉及BCG维持、增强膀胱镜及未来方向相关陈述。
- 方法学和参考文献部分酌情修订。
临床怎么用
- 临床可依据更新后的风险分层框架管理NMIBC患者。
- 应结合生物标志物、亚型组织学等更新陈述进行评估与治疗决策。
- 经尿道切除、膀胱内治疗及BCG维持的更新推荐可用于指导治疗。
- 增强膀胱镜相关更新可用于优化随访与检测策略。
局限性
- 原文未明确报告本次更新的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The survival rate for the majority of patients with non-muscle invasive bladder cancer (NMIBC) is favorable; however, the rates of recurrence and progression to muscle-invasive bladder cancer are important surrogate endpoints for overall prognosis, as these are major determinants of long-term outcome. The recurrence and progression probability rates depend on several clinical and pathologic factors. Therefore, the ability to predict risk of recurrence and progression and treating the disease appropriately is important. This Guideline provides a risk-stratified clinical framework for the management of NMIBC. MATERIALS AND METHODS: During the 2025 update, a modified version of the Guideline search strategy was used to conduct a systematic search of Ovid MEDLINE and Embase for new evidence published between May 2023 and December 2025. The modified search added keywords for newly added therapeutic agents in accordance with the updated populations, interventions, comparators, and outcomes. The systematic search identified 2933 studies, of which 71 studies met inclusion criteria following title and abstract screening. Full-text review resulted in 38 studies being included in the final evidence base. RESULTS: Updates were made to NMIBC risk stratification and statements on biomarkers, subtype histologies, transurethral resection, intravesical therapy, Bacillus Calmette-Guérin maintenance, enhanced cystoscopy, and future directions. Revisions were made to the methodology and reference sections as appropriate. CONCLUSIONS: The Guideline updates herein seek to improve clinicians' ability to evaluate and treat patients with NMIBC based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care.
引用
- Clark PE, Holzbeierlein J, Chang SS, et al. 2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2026. PMID: 42689553. doi:10.1097/JU.0000000000005280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。